THC Therapeutics, Inc.

THC Therapeutics, Inc. (THCT) Annual Report Summary – Fiscal Year Ended July 31, 2024

This summary delves into THC Therapeutics, Inc.'s (THCT) performance, financial health, and strategic direction, drawing directly from its latest SEC 10-K filing for the fiscal year ended July 31, 2024. We aim to present this critical information clearly and concisely for retail investors.

1. Business Overview

THC Therapeutics, Inc. (THCT) operates as a development-stage company primarily focused on the wellness industry. Its core offering is the patented dHydronator® herb dryer, a device designed for the rapid drying and sanitization of freshly harvested cannabis, as well as other herbs, flowers, and tea leaves. The dHydronator® uses UV light to reduce bacteria, drastically cutting drying times from up to two weeks to just 10-14 hours. This innovation addresses critical industry needs for efficiency and compliance with quality control standards by significantly lowering bacterial counts.

The company has a notable history of frequent strategic shifts. Before refocusing on wellness operations and the dHydronator® in 2018, THCT ventured into diverse sectors, including children's parties, aviation, oil and gas, and blockchain technology. This pattern suggests potential strategic instability and a lack of consistent long-term vision.

Currently, the company's strategic direction includes growth through mergers and acquisitions. A key subsequent event, occurring on June 20, 2025, saw THCT acquire The Headquarters Group, Inc. and its subsidiaries by issuing Series D Preferred stock. This move signals the company's intent to expand its footprint and diversify its offerings within the broader cannabis and wellness sectors.

THC Therapeutics operates at the intersection of the wellness and cannabis industries. The evolving regulatory landscape for cannabis presents both opportunities, such as demand for quality control solutions like the dHydronator®, and significant challenges. Key regulatory hurdles include the federal illegality of cannabis in the U.S., which complicates banking, interstate commerce, and investment for its target market. State-level regulations vary widely, creating a fragmented market. The dHydronator®'s sanitization capabilities could become a strong selling point in states with stringent quality and safety testing requirements for cannabis products. The company's past strategic shift from blockchain due to regulatory concerns underscores its sensitivity to external regulatory environments.

2. Financial Performance

THC Therapeutics is a pre-revenue company currently operating at a significant loss. For the fiscal year ending July 31, 2024, the company focused on continued product development and generated no significant operational revenue. The 10-K filing reports no material revenue or profit for the fiscal year, underscoring its development-stage status and reliance on external financing.

• Market Capitalization: As of January 31, 2024, THCT's market capitalization stood at a mere $102,174. This classifies THCT as a highly speculative micro-cap or "penny stock," prone to extreme volatility and illiquidity.
• Shares Outstanding: As of February 10, 2026 (a future date as reported in the filing, which may be a typographical error), the company had 40,266,149 shares of common stock outstanding.

3. Risk Factors

Investors in THC Therapeutics, Inc. face several significant risks, as highlighted in the filing:

• Going Concern & Funding Risk: The company's survival and ability to execute its business plan depend entirely on securing significant additional financing. Failure to raise the estimated $2,000,000 required for commercialization would likely halt dHydronator® development and could lead to the company's collapse.
• Regulatory & Compliance Risk: The company explicitly stated its failure to file all required reports with the SEC during the preceding 12 months. This severe regulatory violation indicates potential governance issues and exposes the company to penalties, delisting risks, and significant investor distrust.
• Market & Competitive Risk: Entering a competitive market dominated by established players like Yofumo Technologies without adequate funding or a proven sales infrastructure poses substantial risk. The dHydronator®'s technological advantages may not be sufficient to overcome significant market entry barriers.
• Execution Risk: Even with funding, successfully transitioning from prototype to mass production, establishing reliable distribution channels, and executing effective marketing in a specialized industry is a complex and high-risk endeavor.
• Stock Volatility & Illiquidity: As a micro-cap stock with a very small public float, THCT's shares are highly volatile and illiquid, making them susceptible to significant price fluctuations and potentially difficult to trade without impacting market price.
• Strategic Instability Risk: The company's history of frequent business model changes suggests a lack of consistent long-term strategy, which could lead to further shifts that dilute focus and shareholder value.
• Cannabis Industry Regulatory Risk: Despite the dHydronator®'s benefits for cannabis, the industry remains subject to complex and evolving federal and state regulations, including federal illegality, banking restrictions, and interstate commerce limitations. These factors could impact market access and growth for the company's target customers.

4. Management Discussion and Analysis (MD&A) Highlights

Management's discussion highlights the company's status as a development-stage entity with no material operational revenue for the fiscal year ended July 31, 2024, resulting in significant losses. The company primarily focused on developing the dHydronator® prototype and securing intellectual property.

Liquidity and Capital Resources: Management emphasizes the company's severe liquidity challenges and its critical need for at least $2,000,000 in available cash or funding. This capital is essential to advance the dHydronator® from its prototype stage to full-scale manufacturing, marketing, and sales. The company holds minimal cash reserves, which are insufficient to fund these planned operations. This substantial funding gap, relative to its minimal market value, highlights significant financial fragility and an immediate need for capital. The company's ability to continue as a "going concern" is highly dependent on its capacity to raise substantial additional capital through equity or debt financing.

Key Developments and Challenges: Management highlights the successful development of a functioning dHydronator® prototype and its protection by a U.S. Patent as significant achievements. Independent lab tests critically validated the dHydronator®'s ability to drastically reduce drying times and significantly lower bacterial counts. After the fiscal year, the company views the acquisition of The Headquarters Group, Inc. as a strategic move to expand and diversify.

However, management acknowledges several major challenges. The most pressing is the critical funding shortfall required for dHydronator® commercialization. Without this capital, manufacturing, marketing, and sales plans cannot proceed, jeopardizing the product's future and the company's viability. Furthermore, management explicitly notes the failure to file all required reports with the SEC during the preceding 12 months, which poses significant regulatory and compliance risks. Management also recognizes intense competition in the herb dryer market and the company's historical strategic instability as ongoing challenges.

5. Financial Health

THC Therapeutics is in a precarious financial state. The stated need for $2,000,000 for commercialization, coupled with its minimal market capitalization and lack of revenue, strongly indicates insufficient cash reserves and severe liquidity constraints. The company's ability to continue as a "going concern" is highly dependent on its capacity to raise substantial additional capital through equity or debt financing. Without this, its operations and strategic plans face a significant risk of failure.

• Cash Position: The company holds minimal cash reserves, which are insufficient to fund its planned operations and commercialization efforts for the dHydronator®.

6. Future Outlook

The company's future outlook is entirely dependent on securing the estimated $2,000,000 in funding. If THCT raises this critical capital, management's plans include:

• Finalizing product design and tooling.
• Manufacturing pre-production units for testing and market presentations.
• Hiring sales and marketing personnel.
• Conducting further detailed lab tests.
• Engaging in market research to explore strategies for sales, distribution, and licensing.

Without this critical funding, these plans cannot materialize, and the company's ability to commercialize the dHydronator® or sustain operations is severely compromised. The company also intends to continue pursuing additional acquisition candidates and strategic opportunities within the cannabis industry as part of its growth strategy.

7. Competitive Position

The dHydronator® aims to differentiate itself through superior speed (10-14 hours vs. traditional 2 weeks) and integrated sanitization (UV light for bacterial reduction). This addresses critical needs for efficiency and product quality in the cannabis and specialty herb markets. The company plans to target both commercial cannabis cultivators and the home herb/garden markets. However, THC Therapeutics acknowledges significant competition from established players like Yofumo Technologies, which already command substantial market share. To gain traction, the company will need to develop a robust and well-funded market entry strategy, including competitive pricing, extensive marketing, and reliable distribution.